Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

Genetron Health4,816 enrolled

Overview

This trail is a multi-center,prospective observational study aimed to detect early-stage Hepatocellular Carcinoma by a Novel Blood-based DNA Methylation Assay(named Genetron HCC Methylation PCR Kit ). The accuracy of the kit will also be evaluated . The trail will be enroll approximately 4816 participants, including participants with HCC or benign diseases, and high risk factors for liver cancer.

Diagnostic performance evaluation: Alpha-fetoprotein (AFP), liver ultrasound (US), dynamic contrast enhanced MRI and the kit examination will be performed on high-risk participants of primary liver cancer. For subjects with typical imaging findings of hepatocellular carcinoma but an intrahepatic nodule diameter of ≤2 cm, an imaging study will be added to the above. According to the clinical diagnostic criteria of primary liver cancer, the diagnostic performance of the kit, liver ultrasound examination (US) combined with alpha fetoprotein (AFP) detection will be evaluated, and the sensitivity of the kit, the kit combined with AFP, the kit combined with AFP and US, AFP combined with US screening for primary liver cancer will be compared. Test performance evaluation: Plasma samples of patients with and without HCC diagnosed according to the clinical diagnostic criteria of primary HCC will be collected and examined simultaneously by the kit and high-throughput human methylation sequencing (NGS sequencing).

Study Type

OBSERVATIONAL

Enrollment

4,816

Conditions

Liver Cancer

Eligibility

Medical Language ↔ Plain English

Diagnostic performance evaluation: Inclusion Criteria: 1. Have high risk factors for liver cancer such as HBV and/or HCV infection, alcoholic liver disease, non-alcoholic steatohepatitis, long-term consumption of food contaminated with aflatoxin, liver cirrhosis caused by various other reasons, and family history of liver cancer Wait; 2. I or my legal representative can read, understand and sign the informed consent; 3. Agree to provide blood samples, be able to receive imaging examinations and have good clinical compliance; 4. The complete clinical basic information includes: the patient's unique traceability number (ID number/outpatient clinic number/medical insurance card number), age, gender, etc. Exclusion Criteria: 1. pregnant women; 2. Have received an organ transplant; 3. Diagnosed with other tumors; 4. The investigators judged that they were not eligible for inclusion. Test performance evaluation: Inclusion Criteria: 1. Confirmed primary hepatocellular carcinoma or confirmed non-HCC; 2. I or my legal representative can read, understand and sign the informed consent; 3. Agree to provide blood samples and have good clinical compliance; 4. The basic clinical information is complete, including: the patient's unique traceability number (ID number/outpatient clinic number/medical insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary liver cancer), imaging examination confirmed non-identical Liver cancer (non-HCC patients). Exclusion Criteria: 1. pregnant women; 2. Have received an organ transplant; 3. Non-HCC patients diagnosed with other tumors; 4. Patients with primary hepatocellular carcinoma combined with other tumors; 5. The investigator judges that they are not eligible for inclusion.

Locations (9)

Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology

Beijing, China

Xiangya Hospital of Central South University

Changsha, China

West China School of Medicine/West China Hospital of Sichuan University

Chengdu, China

Outcomes

Primary Outcomes

All plasma samples and imaging results will be used to evaluate diagnostic(sensitivity and specificity) of the kit.

Alpha-fetoprotein (AFP), liver ultrasound (US), dynamic contrast enhanced MRI and the kit examination will be performed on high-risk participants of primary liver cancer. For subjects with typical imaging findings of hepatocellular carcinoma but an intrahepatic nodule diameter of ≤2 cm, an imaging study will be added to the above. According to the clinical diagnostic criteria of primary liver cancer, the diagnostic performance of the kit, liver ultrasound examination (US) combined with alpha fetoprotein (AFP) detection will be evaluated, and the sensitivity of the kit, the kit combined with AFP, the kit combined with AFP and US, AFP combined with US screening for primary liver cancer will be compared.

Time frame: 2 months

Plasma samples of patients with and without HCC to evaluate test performance(accuracy) of the kit. diagnostic(sensitivity and specificity) of the kit.

Following the principle of simultaneous blinding, blood samples were collected from liver cancer patients and non-HCC patients who had been diagnosed according to the clinical diagnostic criteria for primary liver cancer. The subjects were coded, and the selected samples were tested by the kit and the comparison method high-throughput human methylation sequencing (NGS sequencing method), and the test results were compared.

Time frame: 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.